DrugsControl Media Services

News Detail

Roche wins first approval for subcutaneous Tecentriq (31-08-2023)

Basel, 30 Aug 2023: Roche has beaten competitors to score approval for the subcutaneous (SC) formulation of its blockbuster oncology drug, Tecentriq (atezolizumab).


Tecentriq SC was View Details

Source : Pharmaceutical Technolgy
Roche subcutaneous (SC) formulation oncology drug Tecentriq (atezolizumab) MHRA approved by MHRA

Related News